Quality of life among alcohol-dependent patients: How satisfactory are the available instruments? A systematic review

Drug and Alcohol Dependence

Volumn 125, Issue 3, 2012, Pages 192-202

  Luquiens, A ^a   Reynaud, M ^a   Falissard, B ^a   Aubin, H J ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

Alcohol dependence; Clinical trials; Quality of life; Systematic review

Indexed keywords

ALCOHOLISM; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH STATUS; HUMAN; INTERNAL CONSISTENCY; LIFE SATISFACTION; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; PSYCHOMETRY; QUALITY OF LIFE; REVIEW; SHORT FORM 36; SOCIAL PSYCHOLOGY; SYSTEMATIC REVIEW; VISUAL ANALOG SCALE;

ALCOHOLISM; CLINICAL TRIALS AS TOPIC; HEALTH STATUS; HUMANS; NEUROPSYCHOLOGICAL TESTS; PERSONAL SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS;

EID: 84866351402     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.08.012     Document Type: Review

References (55)

1. Alcohol and Public Policy Group Alcohol: no ordinary commodity-a summary of the second edition. Addiction 2010, 105:769-779.
2. Allen J.P. Measuring outcome in interventions for alcohol dependence and problem drinking: executive summary of a conference sponsored by the national institute on alcohol abuse and alcoholism. Alcohol. Clin. Exp. Res. 2003, 27:1657-1660.
3. Angermeyer, M.C., Kilian, R., Matschinger, H., 2000. Handbuchfür die deutsche Version der WHO InstrumentezurErfassung der Lebensqualität, Göttingen.
4. Arpinelli F., Bamfi F. The FDA guidance for industry on PROs: the point of view of a pharmaceutical company. Health Qual. Life Outcomes 2006, 4:85.
5. Brazier J.E., Harper R., Jones N.M., O'Cathain A., Thomas K.J., Usherwood T., Westlake L. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992, 305:160-164.
6. Carr A.J., Gibson B., Robinson P.G. Measuring quality of life: is quality of life determined by expectations or experience?. BMJ 2001, 322:1240-1243.
7. Cisler R.A., Zweben A. Development of a composite measure for assessing alcohol treatment outcome: operationalization and validation. Alcohol. Clin. Exp. Res. 1999, 23:263-271.
8. Daeppen J.B., Krieg M.A., Burnand B., Yersin B. MOS-SF-36 in evaluating health-related quality of life in alcohol-dependent patients. Am. J. Drug Alcohol Abuse 1998, 24:685-694.
9. Donovan D., Mattson M.E., Cisler R.A., Longabaugh R., Zweben A. Quality of life as an outcome measure in alcoholism treatment research. J. Stud. Alcohol Suppl. 2005, 119-139. (discussion 192-113).
10. Drummond D.C. The relationship between alcohol dependence and alcohol-related problems in a clinical population. Br. J. Addict. 1990, 85:357-366.
11. EMEA Guideline on the Development of Medicinal Products for the Treatment of Alcohol Dependence 2010, EMEA, London.
12. Endicott J., Nee J., Harrison W., Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol. Bull. 1993, 29:321-326.
13. EuroQolGroup EuroQol-a new facility for the measurement of health-related quality of life. Health Pol. 1990, 16:199-208.
14. FDA Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims 2009, U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Center for Devices and Radiological Health (CDRH), Silver Spring, MD, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf.
15. Fertig J.B., Ryan M.L., Falk D.E., Litten R.Z., Mattson M.E., Ransom J., Rickman W.J., Scott C., Ciraulo D., Green A.I., Tiouririne N.A., Johnson B., Pettinati H., Strain E.C., Devine E., Brunette M.F., Kampman K.D.A.T., Stout R. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol. Clin. Exp. Res. 2012, 36:1421-1430.
16. Florez G., Garcia-Portilla P., Alvarez S., Saiz P.A., Nogueiras L., Bobes J. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcohol Clin. Exp. Res. 2008, 32:1251-1259.
17. Florez G., Saiz P.A., Garcia-Portilla P., Alvarez S., Nogueiras L., Bobes J. Topiramate for the treatment of alcohol dependence: comparison with naltrexone. Eur. Addict. Res. 2010, 17:29-36.
18. Gilburt H., Deluca P., Drummond C., Burns T., Copello A., Coulton S., Crawford M., Day E., Godfrey C., Parrott S., Rose A.K., Sinclair J.M.A., Wright C. Assertive community treatment for alcohol dependence (ACTAD): study protocol for a randomised controlled trial. Trials 2012, 13:19.
19. Gual A., Balcells M., Torres M., Madrigal M., Diez T., Serrano L. Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder: a randomized controlled trial. Alcohol Alcohol. 2003, 38:619-625.
20. Gunther O., Roick C., Angermeyer M.C., Konig H.H. The EQ-5D in alcohol dependent patients: relationships among health-related quality of life, psychopathology and social functioning. Drug Alcohol Depend. 2007, 86:253-264.
21. Gunther O.H., Roick C., Angermeyer M.C., Konig H.H. Responsiveness of EQ-5D utility indices in alcohol-dependent patients. Drug Alcohol Depend. 2008, 92:291-295.
22. Higgins J.P., Altman D.G., Gotzsche P.C., Juni P., Moher D., Oxman A.D., Savovic J., Schulz K.F., Weeks L., Sterne J.A. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011, 343:d5928.
23. Janssen M.F., Birnie E., Bonsel G.J. Quantification of the level descriptors for the standard EQ-5D three-level system and a five-level version according to two methods. Qual. Life Res. 2008, 17:463-473.
24. Johnson B.A., Ait-Daoud N., Akhtar F.Z., Ma J.Z. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch. Gen. Psychiatry 2004, 61:905-912.
25. Kiritze-Topor P., Huas D., Rosenzweig C., Comte S., Paille F., Lehert P. A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care. Alcohol Alcohol. 2004, 39:520-527.
26. Koskenvuo, M., 1979. The Finnish Twin Registry Baseline Characteristics, Helsinki.
27. Laaksonen E., Koski-Jannes A., Salaspuro M., Ahtinen H., Alho H. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol. 2008, 43:53-61.
28. Leplège A. Les Mesures de la Qualité de Vie 1999, PUF, Paris.
29. Litten R.Z., Fertig J.B., Falk D.E., Ryan M.L., Mattson M.E., Collins J.F., Murtaugh C., Ciraulo D., Green A.I., Johnson B., Pettinati H., Swift R., Afshar M., Brunette M.F., Tiouririne N.A., Kampman K., Stout R. A double-blind, placebo-controlled trial to assess the efficacy of quetiapinefumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol. Clin. Exp. Res. 2012, 36:406-416.
30. LoCastro J.S., Youngblood M., Cisler R.A., Mattson M.E., Zweben A., Anton R.F., Donovan D.M. Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study. J. Stud. Alcohol Drugs 2009, 70:186-196.
31. Luquiens A., Reynaud M., Aubin H.J. Is controlled drinking an acceptable goal in the treatment of alcohol dependence? A survey of French alcohol specialists. Alcohol Alcohol. 2011, 46:586-591.
32. Macquart-Moulin G., Viens P., Bouscary M.L., Genre D., Resbeut M., Gravis G., Camerlo J., Maraninchi D., Moatti J.P. Discordance between physicians' estimations and breast cancer patients' self-assessment of side-effects of chemotherapy: an issue for quality of care. Br. J. Cancer 1997, 76:1640-1645.
33. Malet L., Llorca P.M., Beringuier B., Lehert P., Falissard B. AlQoL 9 for measuring quality of life in alcohol dependence. Alcohol Alcohol. 2006, 41:181-187.
34. McHorney C.A., Ware J.E., Raczek A.E. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med. Care 1993, 31:247-263.
35. Miller, W.R., 1995. The Drinker Inventory of Consequences (DrInC): An Instrument for Assessing Adverse Consequences of Alcohol Abuse. Project MATCH Monograph Series, vol. 4, NIAAA ed, Rockville, MD.
36. Miller P.G., Miller W.R. What should we be aiming for in the treatment of addiction?. Addiction 2009, 104:685-686.
37. Moraes E., Campos G.M., Figlie N.B., Laranjeira R., Ferraz M.B. Cost-effectiveness of home visits in the outpatient treatment of patients with alcohol dependence. Eur. Addict. Res. 2010, 16:69-77.
38. Muhonen L.H., Lonnqvist J., Juva K., Alho H. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J. Clin. Psychiatry 2008, 69:392-399.
39. Neto D., Lambaz R., Aguiar P., Chick J. Effectiveness of sequential combined treatment in comparison with treatment as usual in preventing relapse in alcohol dependence. Alcohol Alcohol. 2008, 43:661-668.
40. Owens L., Butcher G., Gilmore I., Kolamunnage-Dona R., Oyee J., Perkins L., Walley T., Williamson P., Wilson K., Pirmohamed M. A randomised controlled trial of extended brief intervention for alcohol dependent patients in an acute hospital setting (ADPAC). BMC Public Health 2011, 11:528.
41. Patience D., Buxton M., Chick J., Howlett H., McKenna M., Ritson B. The SECCAT survey: II. The alcohol related problems questionnaire as a proxy for resource costs and quality of life in alcoholism treatment. Study of socio-economic consequences and costs of alcoholism and treatment. Alcohol Alcohol. 1997, 32:79-84.
42. Pettinati H.M., Gastfriend D.R., Dong Q., Kranzler H.R., O'Malley S.S. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcohol. Clin. Exp. Res. 2009, 33:350-356.
43. Rapaport M.H., Clary C., Fayyad R., Endicott J. Quality-of-life impairment in depressive and anxiety disorders. Am. J. Psychiatry 2005, 162:1171-1178.
44. Sareen S., Kumari V., Gajebasia K.S., Gajebasia N.K. Yoga: a tool for improving the quality of life in chronic pancreatitis. World J. Gastroenterol. 2007, 13:391-397.
45. Scott J., Huskisson E.C. Graphic representation of pain. Pain 1976, 2:175-184.
46. Stedman M., Pettinati H.M., Brown E.S., Kotz M., Calabrese J.R., Raines S. A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence. Alcohol. Clin. Exp. Res 2010, 34:1822-1831.
47. Stamler J., Prineas R.J., Neaton J.D., Grimm R.H., McDonald R.H., Schnaper H.W., Schoenberger J.A., Elmer P.J., Cutler J.A. Background and design of the new U.S. trial on diet and drug treatment of "mild" hypertension (TOMHS). Am. J. Cardiol. 1987, 59:51G-60G.
48. Szabo S., WHOQOL Group The World Health Organization Quality of Life (WHOQOL) assessment instrument. Quality of Life and Pharmacoeconomics in Clinical Trials 1996, Lippincott-Raven, Philadelphia, PA. B. Spiker (Ed.).
49. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 1992, 30:473-483.
50. Ware J., Kosinski M., Keller S.D. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med. Care 1996, 34:220-233.
51. Ware J.E. SF-36 health survey update. Spine (Phila Pa 1976) 2000, 25:3130-3139.
52. Willenbring M.L., Olson D.H. A randomized trial of integrated outpatient treatment for medically ill alcoholic men. Arch. Intern. Med. 1999, 159:1946-1952.
53. Williams B.T., Drummond D.C. The Alcohol Problems Questionnaire: reliability and validity. Drug Alcohol Depend. 1994, 35:239-243.
54. Zubaran C., Foresti K. Quality of life and substance use: concepts and recent tendencies. Curr. Opin. Psychiatry 2009, 22:281-286.
55. Zywiak W.H., Kenna G.A., Westerberg V.S. Beyond the ubiquitous relapse curve: a data-informed approach. Front. Psychiatry 2011, 2:12.